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Genome-wide association study identiﬁes
multiple susceptibility loci for glioma
Ben Kinnersley1, Marianne Labussie`re2, Amy Holroyd1, Anna-Luisa Di Stefano2,3,4, Peter Broderick1,
Jayaram Vijayakrishnan1, Karima Mokhtari2,3,5, Jean-Yves Delattre2,3,4, Konstantinos Gousias6, Johannes
Schramm6, Minouk J. Schoemaker1, Sarah J. Fleming7, Stefan Herms8,9, Stefanie Heilmann8, Stefan Schreiber10,11,
Heinz-Erich Wichmann12,13, Markus M. No¨then8, Anthony Swerdlow1,14, Mark Lathrop5,15,16, Matthias Simon6,
Melissa Bondy17, Marc Sanson2,3,4 & Richard S. Houlston1
Previous genome-wide association studies (GWASs) have shown that common genetic
variation contributes to the heritable risk of glioma. To identify new glioma susceptibility loci,
we conducted a meta-analysis of four GWAS (totalling 4,147 cases and 7,435 controls), with
imputation using 1000 Genomes and UK10K Project data as reference. After genotyping an
additional 1,490 cases and 1,723 controls we identify new risk loci for glioblastoma (GBM) at
12q23.33 (rs3851634, near POLR3B, P¼ 3.02 109) and non-GBM at 10q25.2 (rs11196067,
near VTI1A, P¼4.32 108), 11q23.2 (rs648044, near ZBTB16, P¼6.26 10 11), 12q21.2
(rs12230172, P¼ 7.53 10 11) and 15q24.2 (rs1801591, near ETFA, P¼ 5.71 109). Our
ﬁndings provide further insights into the genetic basis of the different glioma subtypes.
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G
liomas account for B40% of all primary brain tumours
and cause around 13,000 deaths in the United States of
America each year1. Gliomas are heterogeneous and
different tumour subtypes, deﬁned in part by malignancy grade
(for example, pilocytic astrocytoma World Health Organization
(WHO) grade I, diffuse ‘low-grade’ glioma WHO grade II,
anaplastic glioma WHO grade III and glioblastoma (GBM) WHO
grade IV) can be distinguished2. Gliomas are typically associated
with a poor prognosis irrespective of clinical care, with the
most common type, GBM, having a median overall survival of
only 10–15 months1.
While the glioma subtypes have distinct molecular proﬁles
resulting from different aetiological pathways3, no environmental
exposures have, however, consistently been linked to risk except
for ionizing radiation, which only accounts for a very small
number of cases1. Direct evidence for inherited predisposition to
glioma is provided by a number of rare inherited cancer
syndromes, such as Turcot’s and Li–Fraumeni syndromes, and
neuroﬁbromatosis4. Even collectively, these diseases however
account for little of the twofold increased risk of glioma seen in
ﬁrst-degree relatives of glioma patients5. Support for polygenic
susceptibility to glioma has come from genome-wide association
studies (GWASs) that have identiﬁed single-nucleotide
polymorphisms (SNPs) at eight loci inﬂuencing glioma risk—
3q26.2 (near TERC), 5p15.33 (near TERT), 7p11.2 (near EGFR),
8q24.21 (near CCDC26), 9p21.3 (near CDKN2A/CDKN2B),
11q23.3 (near PHLDB1), 17p13.1 (TP53) and 20q13.33 (near
RTEL1) (refs 6–10). Perhaps not surprisingly there is variability in
genetic effects on glioma by histology with subtype-speciﬁc
associations at 5p15.33, 20q13.33 and 7p11.2 for GBM and at
11q23.3 and 8q24 for non-GBM glioma6,7.
Recovery of untyped genotypes via imputation has enabled ﬁne
mapping and reﬁnement of association signals, for example, in
identiﬁcation of rs55705857 as the basis of the 8q24 association
signal in glioma11. Recently, the use of the 1000 Genomes Project
and the UK10K projects as a combined reference panel has been
shown to improve accuracy compared with using the 1000
Genomes Project data alone, allowing imputation of alleles with
frequencies B0.5% to be viable12.
Here we report a meta-analysis of four GWASs totalling 4,147
cases and 7,435 controls to identify new glioma susceptibility loci,
after imputation using the 1000 Genomes and the UK10K Project
data as reference. After genotyping an additional series of 1,490
cases and 1,723 controls we identiﬁed new risk loci for GBM at
12q23.33 and non-GBM at 10q25.2, 11q23.2, 12q21.2 and
15q24.2. Our ﬁndings provide further insights into the genetic
basis of the different glioma subtypes.
Results
Association analysis. To identify additional glioma susceptibility
loci we conducted a pooled meta-analysis of four GWASs in
populations of European ancestry, the UK-GWAS, the French-
GWAS, the German-GWAS and the US-GWAS, that were gen-
otyped using either Illumina HumanHap 317, 317þ 240S,
370Duo, 550, 610 or 1M arrays (Supplementary Table 1). After
ﬁltering, the studies provided genotypes on 4,147 cases and 7,435
controls of European ancestry (Supplementary Table 1,
Supplementary Fig. 1). Consistent with our previous analysis6,
quantile–quantile (Q–Q) plots for the German and the US series
showed some evidence of inﬂation (inﬂation factor based on the
90% least-signiﬁcant SNPs, l90¼ 1.15 and 1.11, respectively),
however after correcting for population substructure using
principal-component analyses as implemented in Eigenstrat13,
l90 for all four studies was r1.05 (combined l90¼ 1.05,
Supplementary Fig. 2). To achieve consistent and dense
genome-wide coverage, we imputed unobserved genotypes at
410 million SNPs using a combined reference panel comprising
1,092 individuals from the 1000 Genomes Project and 3,781
individuals from the UK10K project. Q–Q plots for all SNPs
(minor allele frequency (MAF) 40.5%) post-imputation did not
show evidence of substantive over-dispersion introduced by
imputation after Eigenstrat adjustment (combined l90¼ 1.07,
l90 for individual studies¼ 1.04–1.06; Supplementary Fig. 2).
Pooling data from each GWAS into a joint discovery data set,
we derived joint odds ratios (ORs) and 95% conﬁdence intervals
(CIs) under a ﬁxed-effects model for each SNP with MAF40.005
and associated per allele Eigenstrat-corrected P values. Overall
and histology-speciﬁc ORs were derived for all glioma, GBM and
non-GBM. In the pooled data set, associations at the established
risk loci for glioma at 5p15.33, 7p11.2, 8q24.21, 9p21.3, 11q23.3,
17p13.1 and 20q13.33 showed a consistent direction of effect with
previously reported studies (Po5.0 10 8, Fig. 1 and
Supplementary Table 2). In contrast we found no signiﬁcant
support for the association between rs1920116 near TERC
(3q26.2) and risk of high-grade glioma recently reported by
Walsh et al.10 (combined P value for GBM¼ 0.179;
Supplementary Table 2 and Supplementary Fig. 3). While the
UK-GWAS and the study of Walsh et al. share use of UK 1958
Birth Cohort controls, the other three GWAS we analysed are
fully independent.
After ﬁltering at Po5.0 10 6 in either all glioma, GBM or
non-GBM, we selected 14 SNPs for follow-up, mapping to
distinct loci not previously associated with glioma risk (Fig. 1 and
Supplementary Table 2). rs141035288, rs117527984, rs138170678
were not taken forward as there was poor concordance between
imputed and sequenced genotypes (Supplementary Table 3), and
rs145034266 could not be genotyped as it mapped within a highly
repetitive region.
The 10 remaining SNPs underwent replication genotyping in an
additional set of 1,490 glioma cases and 1,723 controls (UK
replication series, Supplementary Table 4). Meta-analysis was then
conducted across discovery and replication stages, with genotype
data available on 5,637 cases and 9,158 controls. In the combined
analysis ﬁve SNPs showed an association with tumour risk, which
was genome-wide signiﬁcant (Table 1)—rs3851634 (12q23.3,
PGBM¼ 3.02 10 9), rs11196067 (10q25.2, PNon-GBM¼
4.32 10 8), rs648044 (11q23.2, PNon-GBM¼ 6.26 10 11),
rs12230172 (12q21.2, PNon-GBM¼ 7.53 10 11) and rs1801591
(15q24.2, PNon-GBM¼ 5.71 10 9). We tested for secondary
signals at each locus by adjusting for the sentinel SNP in each
region, but found no evidence for independent associations
(Supplementary Fig. 4).
The association signal at 12q23.3 deﬁned by rs3851634 was
speciﬁc for GBM. The rs3851634 maps to intron 12 of the gene
encoding polymerase III, RNA, subunit b (POLR3B; Fig. 2a)
within a B350-kb block of linkage disequilibrium (LD) at
12q23.3, which also contains the genes CKAP4 and TCP1L2. The
other four SNP associations deﬁned by rs11196067, rs648044,
rs12230172 and rs1801591 were speciﬁc to non-GBM glioma.
rs11196067 (10q25.2) is located in intron 7 of VTI1A (vesicle
transport through interaction with t-SNAREs 1A, Fig. 2b).
Similarly rs648044 (11q23.2) is also intronic mapping within
ZBTB16 (zinc ﬁnger and BTB domain-containing protein 16,
alias PLZF; Fig. 2c). The rs12230172 (12q21.2) maps within the
lincRNA RP11-114H23.1 and is centromeric to the gene encoding
PHLDA1 (centromeric pleckstrin homology-like domain, family
a, MEMBER 1, Fig. 2d). rs1801591 (15q24.2) is responsible for
the p.Thr171Ile substitution in ETFA (electron transfer ﬂavopro-
tein, alpha polypeptide gene, which resides within a 500-kb region
of LD to which ISL2, TYRO3P and SCAPPER genes also map
Fig. 2e).
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Relationship between the new glioma SNPs and tumour proﬁle.
To investigate the impact of the new risk SNPs on glioma subtype
we examined rs11196067, rs648044, rs12230172, rs1801591
and rs3851634 genotypes in the French case series for
which comprehensive histology and molecular phenotyping
had been performed (Supplementary Data 1). The GBM SNP
rs3851634 was associated with 10q-deleted glioma (P¼ 0.016).
In the case of non-GBM SNPs rs11196067 showed the strongest
association with grade II glioma (P¼ 3.2 10 5) and TP53
non-mutated glioma (P¼ 5.82 10 5); rs648044 with grade II
oligodendroglioma (P¼ 0.026) and 10q non-deleted glioma
(P¼ 0.006); rs1801591 with grade II astrocytoma (P¼ 0.001) and
IDH1/IDH2 mutated glioma (P¼ 0.005) and rs12230172 with
grade II oligodendroglioma (P¼ 0.009), IDH1/IDH2 mutated
(P¼ 0.009) and 10q non-deleted glioma (P¼ 0.003).
Functional annotation of risk variants. For each of the sentinel
risk SNPs at the ﬁve risk loci (as well as correlated variants,
r240.8) we examined published data14,15 and made use of the
online resources HaploReg v3, RegulomeDB and SeattleSeq for
evidence of functionality and regulatory motifs at genomic
regions (Supplementary Table 5). rs1801591, which is responsible
for the ETFA p.Thr171Ile substitution, resides within a highly
conserved region of the genome (genomic evolutionary rate
proﬁling (GERP)¼ 5.65) and the amino-acid change is predicted
to be damaging (PolyPhen¼ 1). Although rs648044 exhibits low
evolutionary conservation (GERP¼  9.32) it maps within a
strong DNase hypersensitivity site and predicted enhancer/super-
enhancer element for multiple tissues including the brain. The
region surrounding rs648044 is also predicted to interact with the
ZBTB16 promoter, which combined with alteration of a Pax-5
motif is suggestive of direct functional impact. rs12230172
localizes within a moderately conserved region (GERP¼ 3.41)
and occupies promoter histone marks in the brain as well as
enhancers predicted to associate with transcriptional start sites for
PHLDA1 and GLIPR1. rs11196067 in VTI1A, while having a low
conservation score (GERP¼ 0.719), occupies enhancer histone
marks in embryonic stem cells although not in brain cells.
Similarly, rs3851634 maps to a moderately conserved region
(GERP¼ 2.37) and occupies enhancer histone marks in 18 organs
including the brain.
eQTL analysis of the ﬁve new glioma SNPs. To gain further
insight into the functional basis of rs11196067, rs648044,
rs12230172, rs1801591 and rs3851634 associations we performed
an expression quantitative trait loci (eQTL) analysis using
RNA-Seq expression data on 389 low-grade gliomas (LGGs) and
138 GBMs from The Cancer Genome Atlas (TCGA), together
with lymphoblastoid cell line RNA-Seq data on 363 samples from
GEUVADIS16. We examined for an association between SNP
genotype and expression of genes mapping within 1Mb of the
sentinel SNP (Supplementary Data 2). After adjusting for
multiple testing within each region no statistically signiﬁcant
eQTL was seen for rs11196067, rs12230172, rs1801591 or
rs3851634. The strongest association between rs648044
genotype and gene expression was with ZW10 in LGG
(P¼ 5.7 10 5), with the risk allele (T) associated with lower
expression, remaining signiﬁcant after adjustment for multiple
testing. To explore the possibility that rs648044 is correlated with
a SNP exhibiting a stronger association with ZW10, we examined
associations with ZW10 expression in LGG tumours in all SNPs
in LD (r240.4) with rs648044. All of the proxy SNPs examined
were more weakly associated with ZW10 than rs648044
(Supplementary Table 6). Following on from these analyses we
made use of publically available eQTL mRNA expression array
data on adipose tissue, lymphoblastoid cell lines and skin from
856 twins (MuTHER17) and 5,311 non-transformed peripheral
blood samples using the blood eQTL browser18. The risk allele
(C) of rs3851634 was associated with signiﬁcantly lower levels of
POLR3B (P¼ 7.49 10 6) in peripheral blood analysis with a
nominally signiﬁcant association in skin (P¼ 0.0052). The risk
allele (T) of rs1801591, was associated with signiﬁcantly lower
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Figure 1 | Genome-wide meta-analysis P values (–log10P, y axis) plotted
against their chromosomal positions (x axis). (a) All glioma, (b) GBM
(c) non-GBM. The red and blue horizontal lines represent signiﬁcance
thresholds of P¼ 5.0 108 and P¼ 5.0 10 6, respectively.
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ETFA levels in peripheral blood (P¼ 7.90 10 12); there was a
nominally signiﬁcant association in MuTHER lymphoblastoid
cell lines (P¼ 0.037).
Somatic mutation of newly implicated risk genes in glioma. We
examined mutation data from TCGA for evidence of recurrent
mutation in genes annotated by the new GWAS signals. Collec-
tively POLR3B, ETFA, VTI1A, ZBTB16 and PHLDA1 are altered
in 8% (22/286) of LGG as compared with 3% (8/273) of GBM
(P¼ 0.014, Supplementary Table 7) providing support for these
genes having a role in glioma tumorigenesis.
Individual variance in risk associated with glioma SNPs. To
explore the relative contributions of previously reported and
newly described loci to glioma risk, we applied the method of
Pharoah et al.19 to eight previously reported SNPs as well as the
ﬁve new risk SNPs (Supplementary Table 8). The variance in risk
attributable to all 12 SNPs is 26%, 27% and 43% for all glioma,
GBM and non-GBM, respectively.
Pathway enrichment of glioma GWAS SNPs. To gain further
insights into the biological basis of associations we performed a
pathway analysis on GWAS associations in all glioma, GBM and
non-GBM. Applying a false discovery rate (FDR) threshold of
o0.1 revealed enrichment for 14 pathways in all glioma, 8 in
GBM and 9 in non-GBM tumours (Supplementary Table 9).
Pathways implicated in GBM tumours primarily include DNA
repair and Notch-signalling, whereas for non-GBM tumours
pathways were primarily associated with cell-cycle progression
and energy metabolism (Supplementary Table 9).
Discussion
To our knowledge we have performed the largest GWAS of
glioma to date, identifying ﬁve novel glioma susceptibility loci at
12q23.33, 10q25.2, 11q23.2, 12q21.2 and 15q24.2 and taking the
total count of risk loci to 12. Through making use of a combined
reference panel from the UK10K and the 1000 Genomes Projects
we were able to recover genotypes from B8 million SNPs for
association analysis, a signiﬁcant increase from using array SNPs
alone. In addition, we have provided further evidence that genetic
susceptibility to glioma can be subtype speciﬁc, emphasising the
importance of searching for histology-speciﬁc risk variants.
While deciphering the functional impact of these SNP
associations on glioma development requires additional analyses,
a number of the genes implicated have relevance to the biology of
this cancer a priori. As well as participating in regulating insulin-
stimulated trafﬁcking of secretory vesicles20, VTI1A plays a key
role in neuronal development and in selectively maintaining
spontaneous neurotransmitter release21. Intriguingly recent
GWAS have identiﬁed associations between the VTI1A SNPs
rs7086803 and lung cancer22 and between rs12241008 and
colorectal cancer23; rs7086803 and rs12241008 are not
Table 1 | Association between SNP and glioma risk in discovery and replication data sets for rs11196067, rs648044, rs12230172,
rs3851634 and rs1801591.
MAF All glioma GBM Non-GBM
SNP Case Control Study P OR (95% CI) P OR (95% CI) P OR (95% CI)
rs111696067 0.38 0.41 FRE 5.00 10 5 0.79 (0.71–0.89) 0.26 0.91 (0.78–1.07) 2.54 106 0.74 (0.66–0.84)
(VTI1A) GER 0.44 0.95 (0.83–1.08) 0.88 1.01 (0.86–1.19) 0.15 0.88 (0.75–1.04)
10q25.2 UK 0.012 0.85 (0.75–0.96) 0.34 0.91 (0.76–1.10) 8.11 10 3 0.81 (0.69–0.95)
A/T USA 0.016 0.88 (0.80–0.98) 0.097 0.90 (0.79–1.02) 0.033 0.87 (0.76–0.99)
Replication 0.56 0.97 (0.88–1.07) 0.91 0.99 (0.89–1.11) 0.33 0.93 (0.81–1.07)
Combined 4.32 106 0.89 (0.85–0.93) 0.11 0.95 (0.89–1.01) 4.32 10 8 0.84 (0.79–0.89)
rs648044 0.40 0.38 FRE 0.019 1.15 (1.02–1.30) 0.93 0.99 (0.83–1.18) 1.76 10 3 1.23 (1.08–1.41)
(ZBTB16) GER 0.043 1.16 (1.00–1.34) 0.39 1.08 (0.90–1.30) 0.016 1.25 (1.04–1.50)
11q23.2 UK 0.78 1.02 (0.89–1.16) 0.044 0.82 (0.67–0.99) 0.037 1.20 (1.01–1.42)
C/T USA 0.088 1.10 (0.99–1.23) 0.62 0.97 (0.86–1.09) 1.02 10 3 1.27 (1.10–1.46)
Replication 0.97 1.08 (0.97–1.19) 0.59 0.97 (0.86–1.09) 4.16 104 1.29 (1.12–1.48)
Combined 5.29 104 1.10 (1.04–1.16) 0.32 0.97 (0.90–1.03) 6.26 10 11 1.25 (1.17–1.34)
rs12230172 0.45 0.46 FRE 0.054 0.90 (0.81–1.00) 0.72 1.03 (0.88–1.20) 4.40 10 3 0.84 (0.74–0.95)
(intergenic) GER 0.043 0.88 (0.77–1.00) 0.84 0.98 (0.84–1.16) 2.17 10 3 0.78 (0.66–0.91)
12q21.2 UK 0.44 0.95 (0.84–1.09) 0.77 0.97 (0.85–1.11) 0.42 0.94 (0.80–1.10)
G/A USA 0.30 0.95 (0.86–1.05) 0.55 1.04 (0.92–1.18) 0.018 0.85 (0.75–0.97)
Replication 1.84 106 0.79 (0.70–0.86) 7.00 10 3 0.85 (0.76–0.96) 3.59 10 8 0.67 (0.58–0.77)
Combined 1.57 106 0.88 (0.84–0.93) 0.22 0.96 (0.91–1.02) 7.53 10 11 0.81 (0.76–0.86)
rs3851634 0.27 0.30 FRE 0.053 0.89 (0.79–1.00) 0.020 0.81 (0.69–0.97) 0.25 0.93 (0.81–1.06)
(POLR3B) GER 0.18 0.91 (0.73–1.04) 0.12 0.87 (0.73–1.04) 0.59 0.95 (0.80–1.14)
12q23.3 UK 0.058 0.88 (0.60–0.89) 1.56 10 3 0.73 (0.60–0.89) 0.92 1.01 (0.85–1.20)
T/C USA 2.84 104 0.81 (0.73–0.91) 7.21 104 0.79 (0.68–0.90) 0.021 0.84 (0.73–0.98)
Replication 0.022 0.88 (0.79–0.98) 5.00 10 3 0.83 (0.74–0.95) 0.57 0.96 (0.83–1.11)
Combined 4.07 10 7 0.87 (0.82–0.92) 3.02 109 0.81 (0.76–0.87) 0.037 0.93 (0.87–1.00)
rs1801591 0.10 0.09 FRE 6.67 10 3 1.32 (1.08–1.61) 0.29 1.17 (0.87–1.58) 2.51 10 3 1.40 (1.13–1.74)
(ETFA) GER 0.037 1.25 (1.01–1.53) 0.17 1.20 (0.93–1.56) 0.052 1.31 (1.00–1.72)
15q24.2 UK 0.44 1.08 (0.88–1.33) 0.93 0.99 (0.73–1.33) 0.23 1.17 (0.90–1.53)
G/A USA 0.016 1.23 (1.04–1.46) 0.97 1.00 (0.80–1.24) 5.13 10 5 1.56 (1.26–1.94)
Replication 0.16 1.13 (0.95–1.33) 0.89 1.01 (0.83–1.23) 0.013 1.31 (1.06–1.63)
Combined 2.75 10 5 1.20 (1.10–1.30) 0.32 1.06 (0.95–1.18) 5.71 109 1.36 (1.23–1.51)
ORs derived with respect to the minor allele, highlighted in bold. The SNPs rs3851634 and rs1801591 were directly genotyped while rs1196067, rs648044 and rs12230172 were imputed with imputation
information scores (Is) of 0.99, 0.87 and 1.00, respectively. Sample sizes in the individual data sets are as follows: FRE (French-GWAS), 1,423 cases and 1,190 controls; GER (German-GWAS), 846 cases
and 1,310 controls; UK (UK-GWAS), 631 cases and 2,699 controls; USA (USA-GWAS), 1,247 cases and 2,236 controls; replication, 1,490 cases and 1,723 controls; combined, 5,637 cases and 9,158
controls. MAF, minor allele frequency in discovery series.
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correlated with each other (r2¼ 0.22, D0 ¼ 0.72) and are also not
correlated with rs11196067 (r2¼ 0.03/0.00 D0 ¼ 1.00/0.22,
respectively), suggesting the existence of multiple risk loci
within the region with different tumour speciﬁcities.
ZBTB16 is highly expressed in undifferentiated, multipotential
progenitor cells and its expression has been shown to
inﬂuence resistance to retinoid-mediated re-differentiation in
t(11;17)(q23;21) acute promyelocytic leukaemia24. The BTB
domain of ZBTB16 has transcriptional repression activity and
interacts with components of the histone deacetylase complex
thereby linking the transcription factor with regulation of
chromatin conformation25. Although rs648044 lies within an
enhancer active in brain and is predicted to interact with the
ZBTB16 promoter, providing an attractive functional basis for the
11q23.2 association through differential ZBTB16 expression, we
found a strong association between rs648044 and ZW10
expression in LGG (P¼ 5.7 10 5). Since ZW10 plays a role
in chromosome segregation26 it also represents a plausible
candidate for the 11q23.2 association.
We also observed a strong association between ETFA expres-
sion and rs1801591 in peripheral blood (P¼ 7.90 10 12).
ETFA participates in mitochondrial fatty acid beta oxidation;
shuttling electrons between ﬂavoprotein dehydrogenases and the
membrane-bound electron transfer ﬂavoprotein ubiquinone
oxidoreductase27. Mutations of ETFA have been reported to be
a cause of recessive glutaric acidaemia IIA (refs 28,29), which
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Figure 2 | Regional plots of discovery-phase association results, recombination rates and chromatin state segmentation tracks for ﬁve glioma-risk
loci. Results for: (a) 12q23.33, rs3851634 (GBM); (b) 10q25.2, rs11196067 (non-GBM); (c) 11q23.2, rs648044 (non-GBM); (d) 12q21.2 rs12230172 (non-
GBM); and (e) 15q24.2, rs1801591 (non-GBM). Plots show discovery association results of both genotyped (triangles) and imputed (circles) SNPs in the
GWAS samples and recombination rates. The  log10 P values (y axes) of the SNPs are shown according to their chromosomal positions (x axes). The lead
SNP in each combined analysis is shown as a large circle or triangle (if imputed or directly genotyped, respectively) and is labelled by its rsID. The colour
intensity of each symbol reﬂects the extent of LD with the top genotyped SNP, white (r2¼0) to dark red (r2¼ 1.0). Genetic recombination rates, estimated
using HapMap samples from Utah residents of western and northern European ancestry (CEU), are shown with a light blue line. Physical positions are
based on NCBI build 37 of the human genome. Also shown are the relative positions of University of Carolina, Santa Cruz (UCSC) genes and transcripts
mapping to the region of association. Genes have been redrawn to show their relative positions; therefore, maps are not to physical scale. Below each plot is
a diagram of the exons and introns of the genes of interest, the associated SNPs and the chromatin state segmentation track (ChromHMM) for H1 neural
progenitor cells derived from the epigenome roadmap project, as per legend. TSS, transcriptional start sites.
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features gliosis. While the p.Thr171Ile change is reported to
decrease thermal stability of ETFA30 thereby providing evidence
for a direct functional effect the strong eQTL data is consistent
with the functional basis for the 15q24.2 association being
mediated through differential expression.
RNA polymerase III (POLR3B) is involved in the transcription
of small noncoding RNAs and short interspersed nuclear
elements, as well as all transfer RNAs31. Although mutations in
POLR3B have been shown to cause recessive hypomyelinating
leukoencephalopathy32 thus far there is no evidence implicating
the gene in the development of glioma. Albeit in peripheral blood
there was a strong association between POLR3B expression and
rs3851634 (P¼ 7.49 10 6), providing a possible functional
basis of the 12q23.2 association.
At 12q21.2 rs12230172 maps within RP11-114H23.1, a
lincRNA of currently unknown function. Although only lying
adjacent to PHLDA1, the known 11q23.3 association maps to the
related gene PHLDB1, which is also speciﬁc to non-GBM
tumours7. Although a role for PHLDA1 in glioma has yet to be
established downregulation of PHLDA1 in neuronal cells has
been shown to enhance cell death without Fas induction33,
additionally PHLDA1 expression may be involved in regulation of
anti-apoptotic effects of IGF1 (ref. 34).
Intriguingly across all of the four GWAS data sets we analysed
we did not replicate the association between rs1920116 (near
TERC) at 3q26.2 and risk of high-grade glioma recently reported
by Walsh et al.10 (P¼ 8.3 10 9, OR¼ 1.30 versus P¼ 0.18,
OR¼ 1.06 relative to the G-allele in our GBM data set), despite
our study having a similar power to demonstrate a relationship
(1,783 GBM cases, 7,435 controls in our study as compared with
1,644 cases, 7,736 controls). It is, however noteworthy that the
Walsh et al. analysed both anaplastic astrocytoma and GBM.
While we could not demonstrate a signiﬁcant association with
either subtype we did see an association between rs1920116 and
TP53-mutated glioma (P¼ 0.016, Supplementary Data 1)
suggesting that the association might be restricted to a speciﬁc
molecularly deﬁned subtype of glioma.
Our ﬁndings provide further evidence for an inherited genetic
susceptibility to glioma. Future investigation of the genes targeted
by the risk SNPs we have identiﬁed is likely to yield increased
insight into the development of this malignancy. We estimate that
the risk loci so far identiﬁed for glioma account for 27 and 43% of
the familial risk of GBM and non-GBM tumours, respectively, of
which 0.8% and 7.6% can be explained by the loci newly reported
in this study (Supplementary Table 8). Although the power of our
study to detect the major common loci (MAF40.2) conferring
risk Z1.2 was high (B80%), we had low power to detect alleles
with smaller effects and/or MAFo0.1. By implication, variants
with such proﬁles probably represent a much larger class of
susceptibility loci for glioma because of the truly small effect sizes
or submaximal LD with tagging SNPs. Thus, it is probable that a
large number of variants remain to be discovered. In addition, as
we have recently shown, stratiﬁed analysis of glioma by molecular
proﬁle may lead to the discovery of additional subtype-speciﬁc
risk variants. However, such subtype analyses can increase
the statistical burden of adjusting for multiple testing.
For example, if applying an additional Bonferroni correction for
GBM and non-GBM subtypes, the rs11196067 (VTI1A) associa-
tion at P¼ 8.64 10 8 would not be declared genome-wide
signiﬁcant. An issue in future subtype analyses of glioma will
therefore be to have sufﬁcient study power to mitigate type II
error given the additional constraints of multiple testing. Further
efforts to expand the scale of GWAS meta-analyses through
international consortia and increasing the number of SNPs taken
forward to large-scale replication will be required to address this
challenge.
Methods
Ethics. Collection of blood samples and clinico-pathological information from
patients and controls was undertaken with informed consent and relevant ethical
review board approval in accordance with the tenets of the Declaration of Helsinki.
Ethical committee approval for this study was obtained from relevant study centres
(UK: South East Multicentre Research Ethics Committee (MREC) and the Scottish
Multicentre Research Ethics Committee; France: APHP Ethical Committee-CPP
(comite´ de Protection des Personnes); Germany: Ethics Commission of the Medical
Faculty of the University of Bonn; and USA: University of Texas MD Anderson
Cancer Institutional Review Board).
Genome-wide association studies. We used GWAS data previously generated on
four non-overlapping case–control series of Northern European ancestry, which
have been the subject of previous studies6,7; summarized in Supplementary Table 1.
Brieﬂy, the UK-GWAS was based on 636 cases (401 males; mean age 46 years)
ascertained through the INTERPHONE study35. Individuals from the 1958
Birth Cohort (n¼ 2,930) served as a source of controls. The US-GWAS was based
on 1,281 cases (786 males; mean age 47 years) ascertained through the MD
Anderson Cancer Center, Texas, between 1990 and 2008. Individuals from the
Cancer Genetic Markers of Susceptibility (CGEMS, n¼ 2,245) studies served as
controls36,37. The French-GWAS study comprised 1,495 patients with glioma
ascertained through the Service de Neurologie Mazarin, Groupe Hospitalier Pitie´-
Salpeˆtrie`re Paris. The controls (n¼ 1,213) were ascertained from the SU.VI.MAX
(SUpplementation en VItamines et MinerauxAntioXydants) study of 12,735
healthy subjects (women aged 35–60 years; men aged 45–60 years)38. The German-
GWAS comprised 880 patients who underwent surgery for a glioma at the
Department of Neurosurgery, University of Bonn Medical Center, between 1996
and 2008. Control subjects were taken from three population studies: KORA
(Co-operative Health Research in the Region of Augsburg; n¼ 488) (ref. 39);
POPGEN (Population Genetic Cohort; n¼ 678) (ref. 40) and from the Heinz
Nixdorf Recall study (n¼ 380) (ref. 41).
Replication genotyping. For replication we made use of DNA from 1,490 glioma
cases recruited to an ongoing UK study of primary brain tumours (National Brain
Tumour Study). Controls were healthy individuals that had been recruited to the
National Study of Colorectal Cancer Genetics42 and the GEnetic Lung CAncer
Predisposition Study43. All cases and controls were UK residents and had self-
reported European ancestry. Controls reported no personal history of cancer at the
time of ascertainment. Genotyping of rs76178334, rs4432939, rs182521816,
rs12780046, rs11196067, rs648044, rs12230172, rs3851634, rs1801591 and
rs78543262 was performed using competitive allele-speciﬁc PCR KASPar
chemistry (LGC, Hertfordshire, UK, primer sequences detailed in Supplementary
Table 10). Conditions used are available on request. Call rates for SNP genotypes
were 495%. To ensure quality of genotyping in all assays, at least two negative
controls and 1–10% duplicates (showing a concordance 499%) were genotyped.
For SNPs with MAFo5%, at least two known heterozygotes were included per
genotyping plate, to aid clustering.
Statistical and bioinformatic analysis. Data were imputed for all scans for over
10 million SNPs using IMPUTE2 v2.3.0 (ref. 44) software and the 1000 Genomes
Project (Phase 1 integrated release 3, March 2012 (ref. 45)) and the UK10K data
(ALSPAC, EGAS00001000090/EGAD00001000195, and TwinsUK,
EGAS00001000108/EGAD00001000194, studies only) as reference panels
(Supplementary Table 1). Genotypes were aligned to the positive strand in both
imputation and genotyping. Imputation was conducted separately for each scan in
which before imputation each GWAS data set was pruned to a common set of
425,190 SNPs. Poorly imputed SNPs deﬁned by an information score (Is) o0.70
and Hardy–Weinberg equilibrium Po1.0 10 5 were excluded from the ana-
lyses. Tests of association between imputed SNPs and glioma was performed under
a probabilistic dosage model in SNPTEST v2.5 (ref. 46).
Eigenvectors for the GWAS data sets were inferred using smartpca (part of
EIGENSOFTv2.4 (refs 13,47)) using B100,00 ld-pruned SNPs. Eigenstrat
adjustment was carried out in SNPTEST by including the ﬁrst 10 eigenvectors as
covariates. The adequacy of the case–control matching and possibility of
differential genotyping of cases and controls was evaluated using Q–Q plots of test
statistics. The inﬂation factor l was based on the 90% least-signiﬁcant SNPs as
previously advocated48. Testing for secondary signals was carried out in SNPTEST,
adjusting for the sentinel SNP using the ‘-condition_on’ option. Visualization of
population ancestry was carried out in smartpca by projecting query samples onto
eigenvectors inferred from the 1000 Genomes Project populations (Supplementary
Fig. 1). Meta-analysis of GWAS data sets under a ﬁxed-effects model was
undertaken in META v1.6 (ref. 49) using the inverse-variance approach. Cochran’s
Q-statistic to test for heterogeneity and the I2 statistic to quantify the proportion of
the total variation due to heterogeneity were calculated50. Phet values o0.05 are
considered characteristic of large heterogeneity50. In addition, analyses stratiﬁed by
glioma tumour histology and molecular characteristics were performed. All
statistical P values were two sided.
Estimates of individual variance in risk associated with glioma-risk SNPs was
carried out using the method described in Pharoah et al.19 assuming the familial
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risk of glioma to be 1.77 (ref. 51). Brieﬂy, for a single allele (i) of frequency p,
relative risk R and ln risk r, the variance (Vi) of the risk distribution due to that
allele is given by:
Vi ¼ 1 pð Þ2E2 þ 2p 1 pð Þ r Eð Þ2 þ p2 2rEð Þ2
Where E is the expected value of r given by:
E ¼ 2p 1 pð Þrþ 2p2r
For multiple risk alleles the distribution of risk in the population tends towards the
normal with variance:
V ¼
X
Vi
The total genetic variance (V) for all susceptibility alleles has been estimated to be
O1.77. Thus the fraction of the genetic risk explained by a single allele is given by:
Vi=V
LD metrics were calculated in vcftools v0.1.12b (ref. 52) using UK10K data and
plotted using visPIG (ref. 53). LD blocks were deﬁned on the basis of HapMap
recombination rate (cM/Mb) as deﬁned using the Oxford recombination hotspots
and on the basis of distribution of conﬁdence intervals deﬁned by Gabriel et al.54
SNPs were annotated for putative functional effect using RegulomeDB55,
HaploReg v3 (ref. 56) and SeattleSeq Annotation 138 (ref. 57). These servers make
use of data from ENCODE58, GERP59 conservation metrics, combined annotation-
dependent depletion (CADD)60 scores and PolyPhen 2 (ref. 61) scores. We
searched for overlap of associated SNPs with enhancers deﬁned by the FANTOM5
enhancer atlas15, annotating by ubiquitous enhancers as well as enhancers
speciﬁcally expressed in astrocytes, neurons, neuronal stem cells and brain tissue.
Similarly, we searched for overlap with ‘super-enhancer’ regions as deﬁned by
Hnisz et al.14, restricting analysis to U87 GBM cells, astrocyte cells and brain tissue.
We additionally made use of 15-state chromHMM data from H1-derived neuronal
progenitor cells available from the Epigenome roadmap project62. Mutation data in
LGG and GBM tumours from TCGA was assessed using the cBioPortal for cancer
genomics63.
To search for biological pathways enriched for glioma SNP associations we
made use of Improved Gene Set Enrichment Analysis for Genome-wide
Association Study (i-GSEA4GWAS v1.1) (ref. 64). SNPs up to 5 kb upstream and
downstream of a given gene were mapped to that gene, with the maximum P value
of all SNPs mapping to a gene used to represent the gene. Gene sets used were:
canonical pathways, gene ontology (GO) biological process, GO molecular
function, GO cellular component. As recommended we applied an FDR cutoff of
o0.10 on all reported gene sets. In the case of multiple identical pathways, that
with the lower FDR value is retained.
Imputation concordance assessment. The ﬁdelity of imputation as assessed by
the concordance between imputed and directly genotyped SNPs was examined in
192 cases and 187 controls from the UK-GWAS discovery series (Supplementary
Table 3). Targeted sequencing for the SNPs rs141035288, rs117527984,
rs76178334, rs4432939, rs182521816, rs138170678, rs145034266, rs12780046,
rs11196067, rs648044, rs12230172 and rs78543262 was performed by Sanger on an
ABI3700 analyser (Applied Biosystems; Supplementary Table 10, conditions are
available on request). For SNPs with MAFo0.05, samples were included to ensure
at least 10 predicted heterozygotes were sequenced. Imputed genotypes were
considered for concordance assessment if exhibiting probability 40.9.
Tumour genotyping. Tumour samples were available from a subset of the patients
ascertained through the Service de Neurologie Mazarin, Groupe Hospitalier Pitie´-
Salpeˆtrie`re Paris. Tumours were snap frozen in liquid nitrogen and DNA was
extracted using the QIAmp DNA minikit, according to the manufacturer’s
instructions (Qiagen, Venlo, LN, USA). DNA was analysed for large-scale copy
number variation by CGH array as previously described65,66. In the cases not
analysed by CGH array, 9p, 10q, 1p and 19q status was assigned using PCR
microsatellites, and EGFR ampliﬁcation and CDKN2A-p16-INK4a homozygous
deletion by quantitative PCR. IDH1, IDH2 and TERT promoter mutation status
was determined by sequencing as previously described67,68.
Expression quantitative trait loci analysis. To examine the relationship between
SNP genotype and gene expression, we made use of tumour RNA sequence data
and blood Affymetrix 6.0 SNP Array data for 389 low-grade and 138 GBM
tumours of European ancestry from TCGA (accession number phs000178.v9.p8),
as well as RNA sequence data from lymphoblastoid cells (GEUVADIS project16)
and genotype data for 363 European individuals from the 1000 Genomes Project45.
Sequence reads from downloaded FASTQ ﬁles were aligned to the human hg19
reference genome and GRCh37 Ensembl transcriptome using TopHat v2.0.7 and
Bowtie v2.0.6. Read counts per gene were generated for 62,069 Ensembl genes
using featureCounts69 as part of the Rsubread Bioconductor package70. For TCGA
samples, European ancestry was assessed through visualization of clustering with
CEU samples after principal components analysis (data not shown). Untyped
genotypes were imputed from the Affymetrix 6 array using similar methods to
those discussed previously. Genotypes with probability 40.9 were taken forward
for eQTL analysis. The association between SNP and gene expression was
quantiﬁed using the Kruskal–Wallis trend test.
We additionally queried publically available eQTL mRNA expression data using
MuTHER, and the Blood eQTL browser. MuTHER contains expression adipose
tissue, lymphoblastoid cells and skin expression data from 856 healthy twins17.
rs500629 was used as a proxy for rs648044 (r2¼ 0.52, D0 ¼ 0.85). The blood eQTL
browser contains expression data from 5,311 non-transformed peripheral blood
samples18. Putative eQTLs were thresholded at FDR o0.1.
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